TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22920644
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for MCN (urgent symptomatic measures and chemotherapy)
Study: 22922531
Drug: Aflibercept 4
Normalized name: aflibercept 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 4 mg/kg IV q14 days (28-day cycles) until disease progression or prohibitive toxicity
Study: 22925036
Drug: Fondaparinux 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 1.5 mg qd for 6 to 15 days
Study: 22925178
Drug: Heparin-grafted membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-grafted membrane with ordinary heparin dose
Study: 22927100
Drug: Scoring balloon
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scoring balloon for side branch and drug-eluting stent for main vessel
Study: 22927248
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell (MSC) treatment
Study: 22929184
Drug: Idursulfase weekly
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idursulfase weekly group
Study: 22929184
Drug: Idursulfase treatment
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idursulfase treatment group (extension phase)
Study: 22930806
Drug: Ciprofloxacin (oral)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (oral) for 14 days
Study: 22935486
Drug: Peginesatide administered
Normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginesatide administered intravenously every 4 weeks for up to 6 doses.
Study: 22935486
Drug: Cohorts using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts using tiered dose conversion tables.
Study: 22935486
Drug: Cohorts using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts using an erythropoiesis-stimulating agent-free interval.
Study: 22935620
Drug: 400-μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-μg sublingual misoprostol as first-line treatment
Study: 22936711
Drug: Riociguat (1.0-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (1.0-2.5 mg three times daily for 12 weeks)
Study: 22939402
Drug: Nexplanon (etonogestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexplanon (etonogestrel implant)
Study: 22939663
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of seven-valent pneumococcal conjugate vaccine (PCV) given at a 4-week interval
Study: 22939663
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of seven-valent pneumococcal conjugate vaccine (PCV)
Study: 22939945
Drug: Extended-release quetiapine
Normalized name: quetiapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release quetiapine
Study: 22940027
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72 h, and 10 mg/kg mefloquine at 96 h
Study: 22941123
Drug: Current medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current medical therapy
Study: 22941849
Drug: Morphine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine bolus for intraoperative analgesia
Study: 22942205
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (<50 nmol/L)
Study: 22943030
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for adherence and depression (CBT-AD), 10 to 12 sessions
Study: 22943074
Drug: Palivizumab 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab 15 mg/kg, administered as 3 to 5 monthly injections over the RSV season.
Study: 22943924
Drug: Anagrelide hydrochloride
Normalized name: Anagrelide Hydrochloride
DrugBank: Anagrelide (DB00261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anagrelide hydrochloride (1 mg BID) in young patients
Study: 22943924
Drug: Anagrelide hydrochloride
Normalized name: Anagrelide Hydrochloride
DrugBank: Anagrelide (DB00261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anagrelide hydrochloride (1 mg BID) in elderly patients
Study: 22944906
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at doses of 0.05, 0.10, and 0.20 μg/kg per minute
Study: 22944906
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion combined with exercise testing
Study: 22946546
Drug: Udenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil (50 mg daily) for 8 weeks
Study: 22951194
Drug: capsule endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule endoscopy
Study: 22952183
Drug: Heme iron
Normalized name: HEME IRON
DrugBank: Ferroheme (DB18267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme iron intake (≥1.63 mg/d)
Study: 22952183
Drug: Total iron
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total iron intake (≥15.09 mg/d)
Study: 22952183
Drug: Liver intake
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver intake (≥100 g/wk)
Study: 22954507
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg orally twice daily in 28-day cycles
Study: 22954655
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine (two doses of a killed whole-cell B-subunit cholera vaccine)
Study: 22954655
Drug: Indirect (herd)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect (herd) protection from the oral cholera vaccine
Study: 22955120
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood serum (CBS) eye drops, 0.15 ng per eye per day epithelial growth factor, administered for 1 month.
Study: 22955317
Drug: Inducible nitric
Normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine hydrochloride
Study: 22955317
Drug: Arginase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginase inhibitor N-hydroxy-nor-l-arginine (nor-NOHA)
Study: 22955317
Drug: Blocking antibodies
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking antibodies for IL-4Rα(+) and IL-10
Study: 22955319
Drug: Steroid-naive asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid-naive asthma
Study: 22955319
Drug: Steroid-using asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid-using asthma
Study: 22959186
Drug: Regorafenib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (160 mg per day)
Study: 22960783
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy program
Study: 22960888
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mononuclear cell therapy (mean 80 million cells, CD-34 + mean 0.92 million)
Study: 22961865
Drug: Selective V(1a)-agonist
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective V(1a)-agonist Phe(2)-Orn(8)-Vasotocin (POV)
Study: 22961865
Drug: Mixed V(1a)-/V(2)-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed V(1a)-/V(2)-agonist AVP
Study: 22963265
Drug: CSF Aβ1-42
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF Aβ1-42 ≤ 192 pG/mL
Study: 22963265
Drug: CSF Aβ1-42
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF Aβ1-42 > 192 pG/mL
Study: 22965160
Drug: Leptin discontinuation
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin discontinuation
Study: 22965568
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for clinically localized melanoma
Study: 22965964
Drug: SB1518 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB1518 (100 to 600 mg/d)
Study: 22967868
Drug: Topical 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.0% bevacizumab for 3 weeks
Study: 22967996
Drug: Neratinib (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (240 mg) plus vinorelbine (25 mg/m2)
Study: 22968742
Drug: COR-1 (10-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: COR-1 (10-240 mg, single i.v. administration)
Study: 22968742
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, single i.v. administration)
Study: 22969149
Drug: pH1N1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH1N1 vaccine (revaccination)
Study: 22969149
Drug: pH1N1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH1N1 vaccine (initial vaccination)
Study: 22969149
Drug: pH1N1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH1N1 vaccine (for LRs)
Study: 22970753
Drug: Albumin excretion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin excretion test for kidney disease
Study: 22971786
Drug: Daniel Fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daniel Fast with krill oil supplementation (2 g/day)
Study: 22971786
Drug: Daniel Fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daniel Fast with placebo supplementation (coconut oil; 2 g/day)
Study: 22972589
Drug: Selumetinib-based combination
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib-based combination therapy (with dacarbazine, docetaxel, temsirolimus, or erlotinib)
Study: 22972589
Drug: Selumetinib-based combination
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib-based combination therapy
Study: 22973678
Drug: Baseline use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline use of B-blockers and aldosterone antagonists
Study: 22973678
Drug: Aldosterone antagonists
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonists and HF education
Study: 22973876
Drug: Drotrecogin alpha
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alpha (activated) (DAA) at 50 ng/ml and 5 μg/ml
Study: 22974533
Drug: (18)F-FMISO dPET-CT
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (18)F-FMISO dPET-CT and functional MRI combined with intensity modulated radiation therapy (IMRT)
Study: 22977195
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m² on day 1 and then 250 mg/m² weekly) in combination with docetaxel (75 mg/m² every 3 weeks or 35 mg/m² on days 1, 8, 15 every 4 weeks)
Study: 22978748
Drug: Vortioxetine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (2.5, 5, 10 mg/day)
Study: 22982655
Drug: Radical local
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical local treatment (surgery or radiotherapy)
Study: 22984218
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg daily; 4 weeks on, 2 weeks off)
Study: 22985379
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg riluzole twice daily for 28 doses, starting at a mean of 8.7 ± 2.2 hours postinjury.
Study: 22987312
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (IM, 400 mg daily)
Study: 22989031
Drug: Preoperative NT-proBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative NT-proBNP < 1028 ng/L
Study: 22990093
Drug: Classic CAH
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic CAH treatment regimen
Study: 22990093
Drug: Nonclassic CAH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonclassic CAH treatment regimen
Study: 22994896
Drug: Intravenous anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthetics
Study: 22995650
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) in the refractory group
Study: 22995650
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) in the naive group
Study: 22998907
Drug: Intravesical oportuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravesical oportuzumab monatox (30 mg) - cohort 1 (6 weekly instillations)
Study: 22998907
Drug: Intravesical oportuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravesical oportuzumab monatox (30 mg) - cohort 2 (12 weekly instillations)
Study: 22998907
Drug: Intravesical oportuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravesical oportuzumab monatox (30 mg)
Study: 22999213
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - calcic nadroparin, administered daily for one month.
Study: 22999213
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - single dose of calcium nadroparin, studied for 12 hours.
Study: 22999294
Drug: Fulvestrant 4
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 4 mg/kg via monthly intramuscular injections for 12 months
Study: 23000649
Drug: Topical thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical thalidomide gel
Study: 23001085
Drug: tacrolimus monotherapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tacrolimus monotherapy with donor bone marrow cell infusion
Study: 23002195
Drug: Implantable cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardiac defibrillator (ICD) therapy
Study: 23006321
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg bid
Study: 23007746
Drug: MMF 4
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 4 g daily
Study: 23009552
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch, mean maintenance dose 3.1 ± 1.1 mg/24 h
Study: 23009652
Drug: PHMB-based gynecological
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHMB-based gynecological solution (Monogin®, Lo.Li. Pharma, Rome - Italy) for six months
Study: 23010851
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral dose of (14)C-dovitinib
Study: 23010851
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily nonlabeled dovitinib (continuous-dosing extension phase)
Study: 23012326
Drug: r-hIL-7 (CYT107)
Normalized name: r-hIL-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hIL-7 (CYT107) administered weekly for 3 weeks
Study: 23014345
Drug: Low-dose IFN-γ
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IFN-γ pretreatment
Study: 23018280
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 or 15 mg/kg) every 3 weeks plus chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression.
Study: 23018547
Drug: Aripiprazole monotherapy
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole monotherapy (10-30 mg/day)
Study: 23018816
Drug: Blood IgG
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood IgG antibody titer test against Porphyromonas gingivalis
Study: 23020932
Drug: Hemoglobin (Hb)
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin (Hb) A(1c), diabetes duration and treatment, particularly with insulin, hypertension, previous cardiovascular disease (CVD), albuminuria
Study: 23025537
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily (MMPI)
Study: 23031215
Drug: Cardioversion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioversion treatment
Study: 23031624
Drug: rilonacept 160
Normalized name: RILONACEPT 160 mg in 2 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Arcalyst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilonacept 160 mg weekly (adults) or 2.2 mg/kg weekly (pediatrics, up to 160 mg)
Study: 23032420
Drug: Topical cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical cidofovir 1% applied for six 2-week cycles
Study: 23032420
Drug: Topical cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical cidofovir 1%
Study: 23032625
Drug: Assay-directed site-specific
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assay-directed site-specific treatment
Study: 23032625
Drug: Assay-directed site-specific
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assay-directed site-specific treatment (responsive tumor types)
Study: 23032625
Drug: Assay-directed site-specific
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assay-directed site-specific treatment (resistant tumor types)
Study: 23032625
Drug: Assay-directed site-specific
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assay-directed site-specific treatment (comparison of responsive vs resistant)
Study: 23033266
Drug: IPH2101 (anti-KIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPH2101 (anti-KIR antibody) administered intravenously every 28 days in 7 dose-escalated cohorts (0.0003-3 mg/kg) for up to 4 cycles.
Study: 23033932
Drug: Pulse dose
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse dose imatinib and weekly paclitaxel
Study: 23034133
Drug: Metformin (increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (increasing doses, 72 hours incubation)
Study: 23034133
Drug: Platelets from
Normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelets from patients with metformin intoxication
Study: 23034910
Drug: Younger age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger age, male sex, less education, poststroke disability, impaired activities of daily living
Study: 23040326
Drug: First-line treatments
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatments were platinum-based combinations with pemetrexed (36.3%), gemcitabine (23.0%), vinorelbine (19.2%), taxanes (18.9%), or other (2.6%), with concurrent targeted agents in 8.4% of patients (mainly bevacizumab, 7.3%).
Study: 23040435
Drug: Overall adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall adherence to G-CSF guidelines
Study: 23040435
Drug: Chemotherapy delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy delivery
Study: 23041588
Drug: Panitumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks
Study: 23041588
Drug: Panitumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks in confirmed KRAS wild-type population
Study: 23041588
Drug: Panitumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks in patients with no identified mutation
Study: 23041595
Drug: FDG uptake
Normalized name: (18F)-FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG uptake in subcutaneous adipose tissue (SAT) of the extremities
Study: 23042966
Drug: Intensity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity of immunosuppressive therapy
Study: 23045577
Drug: Ibrutinib (PCI-32765)
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib (PCI-32765) at doses up to 12.5 mg/kg per day
Study: 23045580
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 20 mg/m2 on days 1 and 15, every 28 days (maximum of six cycles)
Study: 23047045
Drug: Immediate zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate zoledronic acid (4 mg every 6 months for 5 years)
Study: 23047301
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate (20 ml kg)
Study: 23047301
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 130/0.4 (10 ml kg)
Study: 23047301
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ringer's acetate and hydroxyethyl starch
Study: 23047301
Drug: Infusion fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion fluid type
Study: 23051966
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg orally twice a day until disease progression, death, or unacceptable adverse events.